Published recovery field note
Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug designed to cure and prevent all medical device-related infections. Peptilogics’ clinical stage pipeline is led by PLG0206, a novel anti-biofilm therapeutic, currently enrolling the pivotal Ph2/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status.
Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.
Peptilogics is a surgical therapeutics company advancing a novel anti-biofilm drug designed to cure and prevent all medical device-related infections.
Peptilogics’ clinical stage pipeline is led by PLG0206, a novel anti-biofilm therapeutic, currently enrolling the pivotal Ph2/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status.
Connected topics